Zvi Barnea
Wolfson Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zvi Barnea.
Clinical Nutrition | 2013
A. Breslavsky; J. Frand; Z. Matas; Mona Boaz; Zvi Barnea; Marina Shargorodsky
BACKGROUND & AIMS Vitamin D supplementation has the potential to alleviate the cardiovascular damage in diabetic patients. The present study was designed to evaluate long term impact of high doses of vitamin D on arterial properties, glucose homeostasis, adiponectin and leptin in patients with type 2 diabetes mellitus. METHODS AND RESULTS In randomized, placebo-controlled study 47 diabetic patients were assigned into two groups: Group 1 received oral daily supplementation with vitamin D at a dose of 1000 U/day for 12 months. Group 2 received matching placebo capsules. Blood sampling for metabolic parameters, including fasting glucose, lipid profile, HbA1C, insulin, hs-CRP, 25 OH Vit D, adiponectin and leptin was performed at baseline and at the end of the study. Insulin resistance was assessed by homeostasis model assessment (HOMA-IR). Central aortic augmentation index (AI) was evaluated using SphygmoCor. RESULTS The two groups were similar at baseline in terms of hemodynamic parameters. After 12 months, AI decreased significantly during the treatment period in patients received vitamin D (p < 0.0001) and did not change in placebo group. Glucose homeostasis parameters, leptin as well as leptin adiponectin ratio did not change in both groups. 25 OH Vit D level significantly increased (p = 0.022) and circulating adiponectin marginally increased (p = 0.065) during 12 month treatment period in active treatment and did not change in placebo group. CONCLUSIONS High doses of vitamin D supplementation in diabetic patients was associated with significant decrease in AI during one year treatment. This beneficial vascular effect was not associated with improvement in glucose homeostasis parameters.
Nephron Clinical Practice | 2010
Ze’ev Katzir; Mona Boaz; Irena Backshi; Relu Cernes; Zvi Barnea; Alexander Biro
Background: Compliance with treatment regimens is a continuing challenge for chronic dialysis patients and their medical caregivers. Poor patient adherence to prescribed medications can adversely affect treatment outcome. Study Design: In this pre- versus post-intervention study, 89 chronic dialysis patients [75 hemodialysis (HD), 14 continuous ambulatory peritoneal dialysis (CAPD); mean age 62.7 ± 12.39 years, 34 females] responded to a written questionnaire designed to assess knowledge about and compliance with 5 groups of prescribed medications: metabolic drugs, antihypertensives, cardiac-supporting agents, peptic disease therapy and hematological replacement therapy. Mode of intake, storage, means of supply and source of information for each class of drug were also assessed. Patients then received both oral and written instructions regarding their prescribed medications (intervention). This information was repeated 3 months later. Six months after the intervention, patients were re-administered the questionnaires. Response to the questionnaires and laboratory data were compared prior to and following the intervention. Results: Overall, compliance with prescribed medications significantly improved following the intervention, from 89 to 95.7%, p = 0.0007. This relative improvement was greater in HD than CAPD patients (27 vs. 2%, p < 0.0001). Improvement in compliance was associated with lower initial scores, fewer years of education, and longer dialysis vintage. Compared to baseline values, post-intervention blood hemoglobin, hematocrit, mean corpuscular volume, ferritin and Ca levels were significantly improved. Conclusions: Dialysis patients appear to benefit from receiving comprehensive guidance about medications, in terms of compliance with medications and blood chemistry and hematology measures.
Nephron Clinical Practice | 2009
Mona Boaz; Larisa Shtendik; Miriam Oron; Meital Portugal-Cohen; Ron Kohen; Alexander Biro; Relu Cernes; Zvi Barnea; Zeevi Maor; Ze’ev Katzir
Background/Aims: The present study was designed to investigate the short-term safety and efficacy of topical application with body lotion enriched with minerals from the Dead Sea versus 2 different placebo treatments in reducing symptoms of uremic pruritus. Methods: In this single-center, randomized, double placebo-controlled clinical trial, 78 hemodialysis patients with self-reported uremic pruritus were randomized to twice-daily topical treatment with body lotion enriched with minerals from the Dead Sea (DS) or to each of 2 types of placebo: (1) lotion with no Dead Sea minerals but otherwise identical to DS (P1) or (2) lotion with no active ingredients (P2). Symptoms of uremic pruritus (itching, dryness, peeling, tightness) were evaluated at baseline and 2 weeks (14 days) after treatment intervention using a 5-point Likert scale. Results: Following treatment, significant differences in symptom severity scores between DS and P1 and, separately, between group DS and P2, were not detected. Additionally, when DS was compared to the combined placebo groups (P1 and P2 together), significant post-treatment differences in symptom severity scores were not observed. Symptoms were less severe post-treatment regardless of treatment assignment. Conclusions: DS was not superior to either of the placebo treatments in the symptomatic relief of uremic pruritus.
Biomedicine & Pharmacotherapy | 2011
Meital Portugal-Cohen; Miriam Oron; Ze’evi Ma’or; Mona Boaz; Larisa Shtendik; Alexander Biro; Relu Cernes; Zvi Barnea; Ze’ev Kazir; Ron Kohen
BACKGROUND/AIMS Cutaneous manifestations are common in hemodialysis (HD) patients with chronic renal failure (CRF). Associated with uremia, pruritus is a frequently observed symptom in CRF patients and increases with deteriorating renal function. Skin hydrophilic biomarkers (SHB) may be altered in CRF compared to healthy controls. METHODS A noninvasive skin wash sampling technique to detect the expression of SHB, by measuring their secretion on skin surface, was used on HD patients and healthy controls. Hydrophilic antioxidants such as total antioxidant scavenging capacity (TSC) and uric acid (UA) content, and cytokine inflammatory biomarkers such as TNFα and IL-10 levels were estimated. RESULTS Our findings demonstrate significant alterations of the SHB level between HD patients and healthy volunteers. Furthermore, such alterations of secreted SHB correlated markedly with detected changes in blood biochemistry and dermatology severity score. CONCLUSION Skin wash sampling of SHB is a noninvasive technique that distinguishes between HD patients and healthy controls. In HD patients, SHB is associated with biochemical markers in blood and dermatologic symptom severity. This technique is also suggested, as a monitoring tool for diagnosis and treatments of various diseases, in which skin dysfunction is involved.
ICAN: Infant, Child, & Adolescent Nutrition | 2015
Ze’ev Katzir; Alexander Biro; Relu Cernes; Zvi Barnea; Sara Blumberg
Background. Renal injury, proteinuria, and hypertension, are consequences of congenital solitary functioning kidney (CSFK). Renal injury appears around 10 years of age and requires dialysis by the age of 30 years. Low protein intake attenuated renal damage in animal experimental models, uninephrectomized patients, and kidney transplant donors and recipients. Low salt intake facilitates blood pressure control. Objective. Relevant data concerning CSFK patients have not been described so far. We decided to examine long-term preventing effects of protein restriction and low-salt diet on proteinuria, kidney function, and hypertension, in this distinct polulation. Methods. Twenty-eight children with CSFK were included in a prospective observational exposure series. Following parents’ agreement, protein and salt restriction—0.85 × recommended daily allowance (RDA)—was started under dietitian supervision. Compliance verification was performed by (a) monitoring urinary urea nitrogen and body weight, (b) measuring ...
Journal of Renal Nutrition | 2014
Sara Blumberg Benyamini; Zeev Katzir; Alexander Biro; Relu Cernes; Batya Shalev; Tova Chaimy; Zvi Barnea
Clinical Nutrition | 2018
S. Blumberg; Zvi Barnea; R. Cernes; A. Levy; A. Katkov; A. Biro; Z. Katzir
Kidney research and clinical practice | 2012
Sara Blumberg; Zeev Katzir; Alexander Biro; Relu Cernes; Zvi Barnea
/data/revues/07533322/unassign/S0753332211000126/ | 2011
Meital Portugal-Cohen; Miriam Oron; Ze’evi Ma’or; Mona Boaz; Larisa Shtendik; Alexander Biro; Relu Cernes; Zvi Barnea; Ze’ev Kazir; Ron Kohen
/data/revues/07533322/unassign/S0753332211000126/ | 2011
Meital Portugal-Cohen; Miriam Oron; Ze’evi Ma’or; Mona Boaz; Larisa Shtendik; Alexander Biro; Relu Cernes; Zvi Barnea; Ze’ev Kazir; Ron Kohen